This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients (POMX)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by HaEmek Medical Center, Israel.
Recruitment status was:  Not yet recruiting
Information provided by:
HaEmek Medical Center, Israel Identifier:
First received: May 7, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.Furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. The study will try to prove that a polyphenolic extract from pomegranate (POMx) has the same desired effects.

Condition Intervention Phase
Atherosclerosis Drug: POMx Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: May 2007
Estimated Study Completion Date: August 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males
  • HBA1C>7%
  • Drug therapy given for DM

Exclusion Criteria:

  • Age<18
  • Inclusion in another study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00470808

Contact: Wasseem Rock, MD 0547866896

Ha'Emek Medical Center Not yet recruiting
Afula, Israel, 18101
Contact: Wasseem Rock, MD    0547-866806      
Principal Investigator: Wasseem Rock, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Principal Investigator: Wasseem Rock, MD Ha'Emek Medical Center
  More Information Identifier: NCT00470808     History of Changes
Other Study ID Numbers: 0051-07-EMC
Study First Received: May 7, 2007
Last Updated: May 7, 2007

Keywords provided by HaEmek Medical Center, Israel:
Enrollment in another study
HBA1C greater than 7
Drug therapy for DM

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on August 16, 2017